Together, our data demonstrate that while CML cell lines exhibit differential sensitivity to single agent ABT-199, combination with imatinib can enhance the ability of ABT-199 to induce apoptosis in cell lines that express high levels of BCL2. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.